|
|
||||||||
Department of Physiology and Biophysics, University of California, Irvine, California 92697
| |
ABSTRACT |
|---|
|
|
|---|
This brief review presents the basic premises suggesting that insulin-like growth factor I (IGF-I), functioning in an autocrine/paracrine mode, is an important mediator of skeletal muscle adaptation. Key intracellular signaling mechanisms associated with ligation of the primary IGF-I receptor are highlighted to illustrate the mechanisms by which IGF-I may promote muscle hypertrophy. In addition, a number of recent findings are presented that highlight the potential for interactions between IGF-I-related signaling pathways and intracellular signaling mechanisms activated by cytokines or hormonal systems.
insulin-like growth factor I; hypertrophy; cytokine; calcium
| |
INTRODUCTION |
|---|
|
|
|---|
INSULIN-LIKE GROWTH FACTOR I (IGF-I) is the primary mediator of many of the responses regulated by growth hormone in tissues throughout the body (15, 116). In addition, it has long been recognized that IGF-I and IGF-II are important for the pre- and postnatal development of skeletal muscle (13, 38). In the specific context of IGF-I as it relates to muscle, the objectives of this review are twofold: 1) to briefly outline some of the key factors that have led to the continued interest in IGF-I as a potential mediator of loading-induced skeletal muscle adaptation and 2) to widen the discourse on IGF-I via the inclusion of topics that appear to have received less notice in the muscle-related IGF-I literature. The format will be that of a brief review and thus will not be exhaustive in nature. For readers seeking more depth, there are a number of excellent reviews available in the literature (e.g., Ref. 96).
| |
LOCAL CONTROL OF SKELETAL MUSCLE ADAPTATION |
|---|
|
|
|---|
It has become increasingly clear that skeletal muscle is constantly adapting to the functional demands imposed by the load-bearing activities of the individual. In mammalian skeletal muscle, this adaptation process can include changes in both the size and the structural/functional properties of the myofibers. The focus on IGF-I, as well as a number of other growth factors, has been driven in part by the recognition that activity-induced skeletal muscle adaptation is largely mediated by intrinsic mechanisms. Interestingly, a number of studies have demonstrated that adaptations such as muscle hypertrophy can occur even when the somatic milieu would be considered nonanabolic. For example, in rats, the circulating hormone and growth factor milieu can be drastically depressed via surgical hypophysectomy (Hx), which prevents further somatic growth. However, despite this depression of the somatic growth factor environment, the muscles of Hx rats can respond to increased loading with substantial compensatory hypertrophy (40). In this model, the circulating and tissue levels of IGF-I are substantially decreased in Hx rats, but the compensatory hypertrophy process includes a robust increase in the expression of IGF-I mRNA and peptide in the overloaded muscles (2, 30).
| |
MUSCLE REGENERATION |
|---|
|
|
|---|
To understand the importance of intrinsic regulation via autocrine/paracrine signaling, it is instructive to consider some cellular processes, such as myofiber regeneration, which appear to be modulated by IGF-I. In models of severe muscle injury, the death of myofibers leaves behind the basal lamina and some satellite cells. Satellite cells are small mononucleated skeletal muscle stem cells1 located between the basal lamina of the muscle and the sarcolemma of myofibers. As a result of the injury to myofibers, these satellite cells are mobilized to begin the regeneration process (26, 75, 77, 93). The initial events after satellite cell activation have been reported to be a proliferative response in which some or all of the activated satellite cells undergo at least one mitotic cycle (75, 83, 94). After this initial phase, some of the activated cells and/or their progeny are thought to differentiate into myoblast-like cells. In regenerating muscle, these myoblasts can either fuse with each other to form new myofibers or become incorporated into damaged but surviving myofibers (11, 57, 65, 77, 78). If the capacity of satellite cells to proliferate is eliminated, for example via irradiation, the regeneration process is inhibited (26, 42, 75). There is evidence that locally produced, i.e., autocrine/paracrine IGF-I, may be important in this regeneration process. Jennische et al. demonstrated that increased IGF-I immunoreactivity can be detected in the cytoplasm of myoblasts and myotubes (44) as well as in satellite cells (45) during muscle regeneration. Furthermore, the introduction of neutralizing antibodies, which prevent either IGF-I or fibroblast growth factor (FGF-2) activity, has been shown to reduce the number and size of regenerating myofibers after muscle injury with anti-IGF-I treatment demonstrating a higher potency (53).
| |
INTRACELLULAR IGF-I SIGNALING |
|---|
|
|
|---|
With the muscle regeneration process in mind, an examination of
the known effects of IGF-I on skeletal muscle cells provides insight
into potential mechanisms by which this growth factor may contribute to
muscle repair or adaptation. In studies involving both established cell
lines and primary satellite cell cultures, ligation of the type 1 IGF-I
receptor (IGFR1) has been shown to initiate intracellular signaling
cascades involved in key mitogenic and myogenic responses (25,
38, 79). One pathway activated by IGF-I involves Ras-Raf
signaling to extracellular response kinases (ERKs), which can activate
a number of transcription factors as well as other protein kinases. In
muscle cell cultures, this pathway has been shown to promote increased
cell proliferation (Fig. 1) (e.g., Ref.
25). A second pathway involves phosphorylation of insulin
receptor substrate and leads to the activation of phosphatidylinositol 3-kinase (PI3K) (Fig. 2). PI3K activation
is central to a number of important cellular processes, including
protection from apoptosis, increased translation, and
alteration in intracellular calcium. PI3K activation increases the
initiation of translation via alterations in the phosphorylation state
of eukaryotic initiation factor 4 binding protein and the p70 S6 kinase
(Fig. 2). The activation of p70 S6-kinase is of particular interest in
that it enhances the translation of mRNAs encoding ribosomal proteins
and elongation factors, integral components of the protein synthesis
machinery (106). In addition to generalized anabolic
effects, activation of portions of the PI3K signaling cascade appear to
be particularly important for the differentiation of muscle cell lines
in culture (16, 17, 25, 52, 105, 107, 110).
|
|
It is important to note that the activities of the pathways depicted in Figs. 1 and 2 are conditional, i.e., the outcomes are based on a complex set of interactions yet to be comprehensively identified. For example, there are reports that both ERK and PI3K activity act in concert in some cell types (e.g., Refs. 62, 117) and that both may be required for the differentiation of myoblasts (89). In contrast, others have reported that the activity of one pathway may actually inhibit the other (80, 88, 117, 119). As an example of the conditional nature of the effects of signaling through the PI3K pathway, Chakravarthy et al. (19) recently reported that inhibition of PI3K signaling in satellite cell cultures can prevent the completion of the cell cycle, inducing arrest in the G1 phase. Under physiological conditions, G1 arrest would be expected to lead to either cell differentiation or apoptosis. The finding that inhibition of this signaling pathway stimulates cell cycle arrest would suggest that, under some conditions, signaling through PI3K is important for the continuation of cellular proliferation as opposed to the commonly ascribed differentiation response.
Interestingly, the processes of cellular proliferation (i.e., mitotic activity) and differentiation (i.e., expression of muscle-specific proteins) are generally thought to be mutually exclusive. In fact, in a number of cell types, activation of one of the two primary signaling pathways associated with ligation of growth factor receptors (e.g., Fig. 1 vs. Fig. 2) will generally inactivate portions of the other (80, 88). Among the well-characterized growth factors, IGF-I is relatively unique in that it has been reported to stimulate both proliferation and differentiation2, depending on timing and intracellular conditions (84, 108).
The intracellular signaling pathways that subserve IGFR1 ligation also represent potential points for interactions between IGF-I-induced responses and those initiated by other mediators. For example, there is evidence that signaling via G-protein receptors may interact with IGF-I receptor-related pathways modulating or even blocking some responses (e.g., Refs. 48, 58). There is also a growing body of data that suggests that there are interactions between the calcineurin- and IGF-I-signaling pathways in skeletal muscle (e.g., Refs. 29, 67). This is of particular interest in that calcineurin-IGF-I interactions would provide a another mechanism linking cellular calcium homeostasis to IGF-I signaling.
| |
MUSCLE ADAPTATION TO INCREASED LOADING |
|---|
|
|
|---|
There is evidence that the mitogenic and myogenic effects of IGF-I that render it useful for muscle regeneration might also be important for the adaptation of muscle to increased loading as well. A number of in vivo activity models, such as increased loading, stretch, and "eccentric contraction," are known to result in increased IGF-I and/or IGF-I mRNA expression in muscle cells (2, 3, 9, 30, 46, 86, 92, 97, 114, 115). Furthermore, experimental manipulations of muscle IGF-I levels have been shown to induce muscle hypertrophy both in vitro and in vivo (4, 24, 109). For example, overexpression (24) or direct infusion (4) of IGF-I in muscle results in hypertrophy, whereas inhibition of intracellular signaling components associated with IGFR1 ligation can prevent this response (14). Overexpression of IGF-I in muscle has also been shown to prevent some of the age-related effects on skeletal muscle, such as the decline in muscle mass (10, 68). However, muscle IGF-I overexpression in a transgenic model did not prevent atrophy due to acute muscle unloading (27).
| |
THE AUTOCRINE/PARACRINE IGF-I SYSTEM |
|---|
|
|
|---|
One of the more interesting recent developments in the IGF-I story has been the identification of a unique IGF-I isoform that is expressed in response to changes in the loading state of skeletal muscles (115). This isoform, mechanogrowth factor (MGF), has been shown to be markedly upregulated in response to both stretch and increased loading (61, 70). It appears that skeletal muscles produce both a generalized tissue-type IGF-I (1) and the loading-sensitive MGF isoform with differing time courses, suggesting distinct roles for these two growth factor isoforms (70). Expression of both IGF-I and MGF appears to be very sensitive to the loading state of the muscle. For example, we recently found that IGF-I and MGF mRNA increased significantly within a few hours after a single bout of resistance-type exercise in rat muscles (unpublished observations).
In addition to IGF-I itself, there is evidence that cells in muscle produce other components of the IGF-I regulatory system (8, 12, 60). For example, Awede et al. (8) reported that overloaded muscles in mice increased the expression of IGF binding protein 4 (IGFBP4) mRNA, whereas that of IGFBP5 was decreased. In contrast, unloading of mouse muscle resulted in an increase in IGFBP5 mRNA, whereas that of IGFBP4 was unchanged (8). In general, IGFBP4 and IGFBP5 would be expected to modulate the effects of IGF-I via regulation of the free IGF-I concentration in muscle and possibly via competition with IGF receptors for IGF-I (11). These findings provide further support of the idea that the autocrine/paracrine IGF-I system is active in skeletal muscle and sensitive to the loading state of the muscle.
| |
THE "MYOGENIC" COMPONENT OF MUSCLE ADAPTATION |
|---|
|
|
|---|
As with myofiber regeneration, a number of processes that IGF-I is
known to stimulate would also promote skeletal muscle hypertrophy. The
utility of the insulin-like anabolic effects for promoting muscle
hypertrophy is obvious (71, 85). However, the importance of IGF-I-induced actions on muscle satellite cells may be less evident.
In the case of the hypertrophy response, there appears to be a
"myogenic" component wherein satellite cell-derived myoblasts are
thought to fuse with existing myofibers much as they would with damaged
but still viable myofibers after injury (22, 66, 87, 91,
98). The importance of this response stems from the observations
that mature mammalian skeletal muscle fibers appear to maintain a
relatively finite, fiber type-specific relationship between the size of
the myofiber and the number of myonuclei present in a given myofiber
(5, 6, 23, 34, 43, 59, 63, 99, 102, 104). However,
mammalian myofibers become permanently differentiated shortly after
birth and cannot undergo mitotic division or directly increase their
myonuclear number (i.e., myonuclear division) (22). The
requirement for additional nuclei to support hypertrophy appears to be
met via the proliferation, differentiation, and finally the fusion of
muscle satellite cells or their progeny with the enlarging myofibers,
providing the new myonuclei needed to support the hypertrophy process
(5, 63, 72, 81, 82, 91) (Fig.
3). Among the well-characterized growth
factors, IGF-I is the only one that has been consistently reported to
facilitate each of these processes.
|
Interestingly, relatively acute overexpression of IGF-I has been shown to increase the number of times that satellite cells can replicate, possibly explaining some of the palliative effects of this treatment on age-related changes in skeletal muscle cited above (19-21). However, chronic overexpression of IGF-I appears to exhaust the replicative capacity of satellite cell in vivo and thus does not prevent age-related declines in proliferation (21).
| |
IGF-I AND EXCITATION-CONTRACTION COUPLING |
|---|
|
|
|---|
In addition to the anabolic and myogenic effects attributed to IGF-I, this growth factor also appears to have the ability to modulate components of the excitation-contraction coupling mechanism in vivo. Skeletal muscle dihydropyridine receptors (DHPR) are L-type calcium channels that act as the voltage sensor in the transverse tubular system. The primary function of these L-type channels appears to be the detection of depolarization and the direct activation of the calcium release channels in the sarcoplasmic reticulum (49). Unlike the cardiac version of DHPR, the inward current carried by these channels in skeletal muscle does not appear to be important in the acute regulation of excitation contraction coupling (49). However, it is possible that the slow inward conductance of Ca2+ may have some function with regard to long-term intracellular calcium signaling. In cell culture, IGF-I induces an increase in DHPR that results in a significant increase in charge movement (112). In vivo, overexpression of IGF-I in muscle results in a significant increase in DHPR receptor concentration in both fast-twitch and slow-twitch skeletal muscles (74). In addition, IGF-I-induced increases in DHPR appear to ameliorate age-related effects on contractile function in mice (73). To date, the potential impacts of IGF-I on excitation-contraction coupling have received relatively less attention than the myogenic and anabolic aspects detailed above.
| |
IGF-I AND PROINFLAMMATORY CYTOKINES |
|---|
|
|
|---|
There have been reports that prolonged and/or intense exercise may
result in significant increases in circulating levels of proinflammatory cytokines such as interleukin (IL)-6 and/or IL-1
(33, 64, 69, 100, 113). Interestingly, there are reports that exercise can increase proinflammatory cytokines and concurrently depress circulating IGF-I in children (35, 90). In
general, the cellular and molecular effects of exercise-induced
cytokine responses on the IGF-I system have not been extensively
evaluated in the context of exercise. However, it is known that in
disease states such as sepsis the elevated proinflammatory cytokine
levels can either directly or indirectly mediate catabolic effects on skeletal muscle (36, 37, 39, 50, 51, 54, 55). In direct
relation to the IGF-I system, Fan et al. (36) found that systemic injection of IL-1
or tumor necrosis factor-
(TNF-
) resulted in a reduction in muscle IGF-I in rats. In a similar finding,
Lang et al. (50) reported that systemic sepsis is
associated with a decline in skeletal muscle and plasma IGF-I. These
authors found that blocking the IL-1 receptor prevented the decline of IGF-I in skeletal muscle and reduced the degree of IGF-I decrease seen
in the plasma. The IL-1 blockade also prevented the 43% decrease in
skeletal muscle protein synthesis-induced by the septic state. Thus it
appears that the anti-anabolic and/or catabolic effects of cytokines
such as IL-1
may be mediated at least in part via the IGF-I axis.
In addition to indirect effects such as a decrease in circulating IGF-I, there is evidence that some cytokines may interact with intracellular IGF-I receptor signaling. One area of intersection involves intracellular signaling via the Janus-activated kinases (JAK) and signal transducers and activators of transcription (STAT), which participate in cytokine signaling (47). Recent evidence suggests that the IGF-I receptor may also activate JAK/STAT signaling (41, 56, 103, 120). Among the targets for STATs are a family of suppressors of cytokine signaling, which act as part of a negative feedback loop to the cytokine receptors. This raises the possibility that elevated cytokine signaling could also feedback to and possibly inhibit the IGF-I receptor as well (31, 32, 103). This would provide an indirect mechanism for the inhibition of IGF-I signaling whereby increased proinflammatory cytokine levels might stimulate the production of suppressors of cytokine signaling, which would then feedback to both the cytokine and IGF-I receptors. It is also possible that proinflammatory cytokines modulate IGF-I less directly via increasing circulating corticosteroid levels (51). Both endogenous and exogenous glucocorticoids are known to modulate both IGF-I abundance and IGF-I effects in muscle (28, 36, 51, 95, 96).
In a seemingly paradoxical set of findings, it has been shown that the
proinflammatory cytokines IL-6 and TNF-
stimulate the proliferation
of satellite cells or myoblasts in vitro (7, 18, 101,
111). This suggests that there may be a role for components of
the inflammatory response in muscle adaptation (111). It
is tempting to speculate that a potential role of inflammatory responses in muscle adaptation may be a function of the degree of
response and as such that this may be one of the mechanisms that
separates training from overtraining (97).
| |
SUMMARY |
|---|
|
|
|---|
The continued interest in the role of IGF-I in skeletal muscle adaptation is founded on the extensive body of evidence indicating that 1) IGF-I is both anabolic and mitogenic for skeletal muscle or muscle lineage cells, 2) IGF-I operates in an autocrine/paracrine mode in skeletal muscle, and 3) muscle IGF-I and MGF production are sensitive to increases in loading state. In addition to the effects of IGF-I in promoting skeletal muscle hypertrophy or regeneration, there are a number of other systems that may impact or be impacted by IGF-I signaling that should be considered by muscle researchers. Future challenges in this area include the identification of the cellular level mechanisms that transduce mechanical signals leading to changes in IGF-I signaling and elucidation of the relationships between the various intracellular signaling pathways that allow IGF-I signaling to stimulate the competing processes of cellular differentiation and cellular proliferation.
| |
FOOTNOTES |
|---|
Address for reprint requests and other correspondence: G. R. Adams, Univ. of California Irvine, Dept. of Physiology & Biophysics, 346-D Medical Sciences 1, Irvine, CA 92697-4560 (E-mail: gradams{at}uci.edu).
1 There is evidence that multiple muscle stem cell populations may be contributing to processes traditionally ascribed to satellite cells (e.g., Refs. 26, 118).
2 A number of growth factors, such as FGF-6 and hepatocyte growth factor, are being actively investigated in this respect, but to date the results have not proved conclusive in in vivo models.
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
10.1152/japplphysiol.01264.2001
| |
REFERENCES |
|---|
|
|
|---|
1.
Adamo, ML,
Neuenschwander S,
LeRoith D,
and
Roberts CT.
Structure, expression, and regulation of the IGF-I gene.
Adv Exp Med Biol
343:
1-11,
1993[Medline].
2.
Adams, GR,
and
Haddad F.
The relationships between IGF-1, DNA content, and protein accumulation during skeletal muscle hypertrophy.
J Appl Physiol
81:
2509-2516,
1996
3.
Adams, GR,
Haddad F,
and
Baldwin KM.
Time course of changes in markers of myogenesis in overloaded rat skeletal muscles.
J Appl Physiol
87:
1705-1712,
1999
4.
Adams, GR,
and
McCue SA.
Localized infusion of IGF-I results in skeletal muscle hypertrophy in rats.
J Appl Physiol
84:
1716-1722,
1998
5.
Allen, DL,
Monke SR,
Talmadge RJ,
Roy RR,
and
Edgerton VR.
Plasticity of myonuclear number in hypertrophied and atrophied mammalian skeletal muscle fibers.
J Appl Physiol
78:
1969-1976,
1995
6.
Allen, DL,
Yasui W,
Tanaka T,
Ohira Y,
Nagaoka S,
Sekiguchi C,
Hinds WE,
Roy RR,
and
Edgerton VR.
Myonuclear number and myosin heavy chain expression in rat soleus single muscle fibers after spaceflight.
J Appl Physiol
81:
145-151,
1996
7.
Austin, L,
Bower J,
Kurek J,
and
Vakakis N.
Effects of leukaemia inhibitory factor and other cytokines on murine and human myoblast proliferation.
J Neurol Sci
112:
185-191,
1992[Web of Science][Medline].
8.
Awede, B,
Thissen J,
Gailly P,
and
Lebacq J.
Regulation of IGF-I, IGFBP-4 and IGFBP-5 gene expression by loading in mouse skeletal muscle.
FEBS Lett
461:
263-267,
1999[Web of Science][Medline].
9.
Bamman, MM,
Shipp JR,
Jiang J,
Gower BA,
Hunter GR,
Goodman A,
McLafferty CL,
and
Urban RJ.
Mechanical load increases muscle IGF-I and androgen receptor mRNA concentrations in humans.
Am J Physiol Endocrinol Metab
280:
E383-E390,
2001
10.
Barton-Davis, ER,
Shoturma DI,
Musaro A,
Rosenthal N,
and
Sweeney HL.
Viral mediated expression of insulin-like growth factor I blocks the aging-related loss of skeletal muscle function.
Proc Natl Acad Sci USA
95:
15603-15607,
1998
11.
Baxter, RC.
Insulin-like growth factor (IGF)-binding proteins: interactions with IGFs and intrinsic bioactivities.
Am J Physiol Endocrinol Metab
278:
E967-E976,
2000
12.
Bayol, S,
Loughna PT,
and
Brownson C.
Phenotypic expression of IGF binding protein transcripts in muscle, in vitro and in vivo.
Biochem Biophys Res Commun
273:
282-286,
2000[Web of Science][Medline].
13.
Benito, M,
Valverde AM,
and
Lorenzo M.
IGF-1: a mitogen also involved in differentiation processes in mammalian cells.
Int J Biochem Cell Biol
28:
499-510,
1996[Web of Science][Medline].
14.
Bodine, SC,
Stitt TN,
Gonzalez M,
Kline WO,
Stover GL,
Bauerlein R,
Zlotchenko E,
Scrimgeour A,
Lawrence JC,
Glass DJ,
and
Yancopoulos GD.
Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo.
Nat Cell Biol
3:
1014-1019,
2001[Web of Science][Medline].
15.
Butler, AA,
and
LeRoith D.
Control of growth by the somatropic axis: growth hormone and the insulin-like growth factors have related and independent roles.
Annu Rev Physiol
63:
161-164,
2001.
16.
Calera, MR,
and
Pilch PF.
Induction of Akt-2 correlates with differentiation in Sol8 muscle cells.
Biochem Biophys Res Commun
251:
835-841,
1998[Web of Science][Medline].
17.
Canicio, J,
Gallardo E,
Illa I,
Testar X,
Palacin M,
Zorzano A,
and
Kaliman P.
p70 S6 kinase activation is not required for insulin-like growth factor-induced differentiation of rat, mouse or human skeletal muscle cells.
Endocrinology
139:
5042-5049,
1998
18.
Cantini, M,
Massimino ML,
Rapizzi E,
Rossini K,
Catani C,
Libera LD,
and
Carraro U.
Human satellite cell proliferation in vitro is regulated by autocrine secretion of IL-6 stimulated by a soluble factor(s) released by activated monocytes.
Biochem Biophys Res Commun
216:
49-53,
1995[Web of Science][Medline].
19.
Chakravarthy, MV,
Abraha TW,
Schwartz RJ,
Fiorotto ML,
and
Booth FW.
Insulin-like growth factor-I extends in vitro replicative life span of skeletal muscle satellite cells by enhancing G1/S cell cycle progression via the activation of phosphatidylinositol 3'-kinase/Akt signaling pathway.
J Biol Chem
275:
35942-35952,
2000
20.
Chakravarthy, MV,
Davis BS,
and
Booth FW.
IGF-I restores satellite cell proliferative potential in immobilized old skeletal muscle.
J Appl Physiol
89:
1365-1379,
2000
21.
Chakravarthy, MV,
Fiorotto ML,
Schwartz RJ,
and
Booth FW.
Long-term insulin-like growth factor-I expression in skeletal muscles attenuates the enhanced in vitro proliferation ability of the resident satellite cells in transgenic mice.
Mech Ageing Dev
122:
1303-1320,
2001[Web of Science][Medline].
22.
Chambers, RL,
and
McDermott JC.
Molecular basis of skeletal muscle regeneration.
Can J Appl Physiol
21:
155-184,
1996[Medline].
23.
Cheek, DB,
Holt AB,
Hill DE,
and
Talbert JL.
Skeletal muscle mass and growth: the concept of the deoxyribonucleic acid unit.
Pediatr Res
5:
312-328,
1971[Web of Science].
24.
Coleman, ME,
DeMayo F,
Yin KC,
Lee HM,
Geske R,
Montgomery C,
and
Schwartz RJ.
Myogenic vector expression of insulin-like growth factor I stimulates muscle cell differentiation and myofiber hypertrophy in transgenic mice.
J Biol Chem
270:
12109-12116,
1995
25.
Coolican, SA,
Samuel DS,
Ewton DZ,
McWade FJ,
and
Florini JR.
The mitogenic and myogenic actions of insulin-like growth factors utilize distinct signaling pathways.
J Biol Chem
272:
6653-6662,
1997
26.
Creuzet, S,
Lescaudron L,
Li Z,
and
Fontaine-Perus J.
MyoD, myogenin, and desmin-nls-lacZ transgene emphasize the distinct patterns of satellite cell activation in growth and regeneration.
Exp Cell Res
243:
241-253,
1998[Web of Science][Medline].
27.
Criswell, DS,
Booth FW,
DeMayo F,
Schwartz RJ,
Gordon SE,
and
Fiorotto ML.
Overexpression of IGF-I in skeletal muscle of transgenic mice does not prevent unloading-induced atrophy.
Am J Physiol Endocrinol Metab
275:
E373-E379,
1998
28.
Dardevet, D,
Sornet C,
Savary I,
Debras E,
Patureau-Mirand P,
and
Grizard J.
Glucocorticoid effects on insulin- and IGF-I-regulated muscle protein metabolism during aging.
J Endocrinol
156:
83-89,
1998[Abstract].
29.
Delling, U,
Tureckova J,
Lim HW,
De Windt LJ,
Rotwein P,
and
Molkentin JD.
A calcineurin-NFATc3-dependent pathway regulates skeletal muscle differentiation and slow myosin heavy-chain expression.
Mol Cell Biol
20:
6600-6611,
2000
30.
DeVol, DL,
Rotwein P,
Sadow JL,
Novakofski J,
and
Bechtel PJ.
Activation of insulin like growth factor gene expression during work induced skeletal muscle growth.
Am J Physiol Endocrinol Metab
259:
E89-E95,
1990
31.
Dey, BR,
Furlanetto RW,
and
Nissley P.
Suppressor of cytokine signaling (SOCS)-3 protein interacts with the insulin-like growth factor-I receptor.
Biochem Biophys Res Commun
278:
38-43,
2000[Web of Science][Medline].
32.
Dey, BR,
Spence SL,
Nissley P,
and
Furlanetto RW.
Interaction of human suppressor of cytokine signaling (SOCS)-2 with the insulin-like growth factor-I receptor.
J Biol Chem
273:
24095-24101,
1998
33.
Drenth, JPH,
Van Uum SHM,
Van Deuren M,
Pesman GJ,
Van Der Ven-Jongekrijg J,
and
Van Der Meer JWM
Endurance run increases circulating IL-6 and IL-1re but downregulates ex vivo TNF-
and IL-1
production.
J Appl Physiol
79:
1497-1503,
1995
34.
Edgerton, VR,
and
Roy RR.
Regulation of skeletal muscle fiber size, shape and function.
J Biomech
24:
123-133,
1991.
35.
Eliakim, A,
Scheett TP,
Newcomb R,
Mohan S,
and
Cooper DM.
Fitness, training, and the growth hormone insulin-like growth factor I axis in prepubertal girls.
J Clin Endocrinol Metab
86:
2797-2802,
2001
36.
Fan, J,
Wojnar MM,
Theodorakis M,
and
Lang CH.
Regulation of insulin like growth factor (IGF)-1 mRNA and peptide and IGF-binding proteins by interleukin-1.
Am J Physiol Regul Integr Comp Physiol
270:
R621-R629,
1996
37.
Fang, CH,
Li BG,
James H,
Fischer JE,
and
Hasselgren PO.
Cytokines block the effects of insulin-like growth factor-1 on glucose uptake and lactate production in skeletal muscle but do not influence IGF-I-induced changes in protein turnover.
Shock
8:
362-367,
1997[Web of Science][Medline].
38.
Florini, JR,
Ewton DZ,
and
Coolican SA.
Growth hormone and insulin like growth factor system in myogenesis.
Endocr Rev
17:
481-517,
1996
39.
Garcia-Martinez, C,
Llovera M,
Agell N,
Lopez-Soriano FJ,
and
Argiles JM.
Ubiquitin gene expression in skeletal muscle is increased during sepsis: Involvement of TNF-
but not IL-1.
Biochem Biophys Res Commun
217:
839-844,
1995[Web of Science][Medline].
40.
Goldberg, AL.
Work induced growth of skeletal muscle in normal and hypophysectomized rats.
Am J Physiol
213:
1193-1198,
1967
41.
Gual, P,
Baron V,
Lequoy V,
and
Van Obberghen E.
Interaction of janus kinases JAK-1 and JAK-2 with the insulin receptor and the insulin-like growth factor-1 receptor.
Endocrinology
139:
884-893,
1998
42.
Gulati, AK.
The effect of X-irradiation on skeletal muscle regeneration in the adult rat.
J Neurol Sci
78:
111-120,
1987[Web of Science][Medline].
43.
Hikida, RS,
Van Nostran S,
Murray JD,
Staron RS,
Gordon SE,
and
Kraemer WJ.
Myonuclear loss in atrophied soleus muscle fibers.
Anat Rec
247:
350-354,
1997[Medline].
44.
Jennische, E,
and
Hansson HA.
Regenerating skeletal muscle cells express insulin-like growth factor 1.
Acta Physiol Scand
130:
327-332,
1987[Web of Science][Medline].
45.
Jennische, E,
Skottner A,
and
Hansson HA.
Satellite cells express the trophic factor IGF-1 in regenerating skeletal muscle.
Acta Physiol Scand
129:
9-15,
1987[Web of Science][Medline].
46.
Keller, HL,
St B. Pierre Schneider Eppihimer LA,
and
Cannon JG.
Association of IGF-I and IGF-II with myofiber regeneration in vivo.
Muscle Nerve
22:
347-354,
1999[Web of Science][Medline].
47.
Kelso, A.
Cytokines: principles and prospects.
Immunol Cell Biol
76:
300-317,
1998[Medline].
48.
Kim, S,
Jee K,
Kim D,
Koh H,
and
Chung J.
Cyclic AMP inhibits Akt activity by blocking the membrane localization of PDK1.
J Biol Chem
276:
12864-12870,
2001
49.
Lamb, GD.
Excitation-contraction coupling in skeletal muscle: comparisons with cardiac muscle.
Clin Exp Pharmacol Physiol
27:
216-224,
2000[Web of Science][Medline].
50.
Lang, CH,
Fan J,
Coney R,
and
Vary TC.
IL-1 receptor antagonist attenuates sepsis-induced alterations in the IGF system and protein synthesis.
Am J Physiol Endocrinol Metab
270:
E340-E437,
1996.
51.
Lang, CH,
Fan J,
Wojnar MM,
Vary TC,
and
Cooney R.
Role of central IL-1 in regulating peripheral IGF-I during endotoxemia and sepsis.
Am J Physiol Regul Integr Comp Physiol
274:
R956-R962,
1998
52.
Lawlor, MA,
and
Rotwein P.
Insulin-like growth factor-mediated muscle cell survival: central roles for Akt and cyclin-dependent kinase inhibitor p21.
Mol Cell Biol
20:
8983-8995,
2000
53.
LeFaucheur, JP,
and
Sebille A.
Muscle regeneration following injury can be modified in vivo by immune neutralization of fibroblast growth factor, transforming growth factor
1 or insulin-like growth factor I.
J Neuroimmunol
57:
85-91,
1995[Web of Science][Medline].
54.
Ling, PR,
Schwartz JH,
and
Bistrian BR.
Mechanisms of host wasting induced by administration of cytokines in rats.
Am J Physiol Endocrinol Metab
272:
E333-E339,
1997
55.
Llovera, M,
Garcia-Martinez C,
Agell N,
Lopez-Soriano F,
and
Argiles JM.
TNF can directly induce the expression of ubiquitin-dependent proteolytic system in rat soleus muscles.
Biochem Biophys Res Commun
230:
238-241,
1997[Web of Science][Medline].
56.
Lopaczynski, W.
Differential regulation of signaling pathways for insulin and insulin-like growth factor I.
Acta Biochim Pol
46:
51-61,
1999[Web of Science][Medline].
57.
Luque, E,
Pena J,
Salas P,
and
Martin JD.
Changes in satellite cell population associated with regenerating muscle fibers in rats.
J Submicrosc Cytol Pathol
28:
305-311,
1996[Web of Science][Medline].
58.
Malbon, CC,
and
Karoor V.
G-protein-linked receptors as tyrosine kinase substrates: New paradigms in signal integration.
Cell Signal
10:
523-527,
1998[Web of Science][Medline].
59.
McCall, GE,
Allen DL,
Linderman JK,
Grindeland RE,
Roy RR,
Mukku VR,
and
Edgerton VR.
Maintenance of myonuclear domain size in rat soleus after overload and growth hormone/IGF-I treatment.
J Appl Physiol
84:
1407-1412,
1998
60.
McCusker, RH,
and
Clemmons DR.
Effects of cytokines on insulin-like growth factor binding protein secretion by muscle cells in vitro.
Endocrinology
134:
2095-2102,
1994[Abstract].
61.
McKoy, G,
Ashley W,
Mander J,
Yang SY,
Williams N,
Russell B,
and
Goldspink G.
Expression of insulin growth factor-1 splice variants and structural genes in rabbit skeletal muscle induced by stretch and stimulation.
J Physiol
516:
583-592,
1999
62.
Mehrhof, FB,
Muller FU,
Bergmann MW,
Li P,
Wang Y,
Schmitz W,
Dietz R,
and
von Harsdorf R.
In cardiomyocyte hypoxia, insulin-like growth factor-I-induced antiapoptotic signaling requires phosphatidylinositol-3-OH-kinase-dependent and mitogen-activated protein kinase-dependent activation of the transcription factor cAMP response element-binding.
Circulation
104:
2088-2094,
2001
63.
Mitchell, PO,
and
Pavlath GK.
A muscle precursor cell-dependent pathway contributes to muscle growth after atrophy.
Am J Physiol Cell Physiol
281:
C1706-C1715,
2001
64.
Moldoveanu, AI,
Shephard RJ,
and
Shek PN.
Exercise elevates plasma levels but not gene expression of IL-1
, IL-6 and TNF-
in blood mononuclear cells.
J Appl Physiol
89:
1499-1504,
2000
65.
Molnar, G,
Ho ML,
and
Schroedl NA.
Evidence for multiple satellite cell populations and a non-myogenic cell type that is regulated differently in regenerating and growing skeletal muscle.
Tissue Cell
28:
547-556,
1996[Web of Science][Medline].
66.
Moss, FP,
and
Leblond CP.
Satellite cells as the source of nuclei in muscles of growing rats.
Anat Record
170:
421-436,
1971[Medline].
67.
Musarò, A,
McCullagh KJ,
Naya FJ,
Olson EN,
and
Rosenthal N.
IGF-1 induces skeletal myocyte hypertrophy through calcineurin in association with GATA-2 and NF-ATc1.
Nature
400:
581-584,
1999[Medline].
68.
Musarò, A,
McCullagh K,
Paul A,
Houghton L,
Dobrowolny G,
Molinaro M,
Barton ER,
Sweeney HL,
and
Rosenthal N.
Localized Igf-1 transgene expression sustains hypertrophy and regeneration in senescent skeletal muscle.
Nat Genet
27:
195-200,
2001[Web of Science][Medline].
69.
Nieman, DC.
Immune response to heavy exertion.
J Appl Physiol
82:
1385-1394,
1997
70.
Owino, V,
Yang SY,
and
Goldspink G.
Age-related loss of skeletal muscle function and the inability to express the autocrine form of insulin-like growth factor-1 (MGF) in response to mechanical overload.
FEBS Lett
505:
259-263,
2001[Web of Science][Medline].
71.
Petley, T,
Graff K,
Jiang W,
and
Florini J.
Variation among cell types in the signaling pathways by which IGF-I stimulates specific cellular responses.
Horm Metab Res
31:
70-76,
1999[Web of Science][Medline].
72.
Phelan, JN,
and
Gonyea WJ.
Effect of radiation on satellite cell activity and protein expresion in overloaded mammalian skeletal muscle.
Anat Rec
247:
179-188,
1997[Medline].
73.
Renganathan, M,
Messi ML,
and
Delbono O.
Over expression of IGF-1 exclusively in skeletal muscle prevents age-related decline in the number of dihydropyridine receptors.
J Biol Chem
273:
28845-28851,
1998
74.
Renganathan, M,
Messi ML,
Schwartz R,
and
Delbono O.
Over expression of IGF-1 exclusively in skeletal muscle increases the number of dihydropyridine receptors in adult transgenic mice.
FEBS Lett
417:
13-16,
1997[Web of Science][Medline].
75.
Robertson, TA,
Grounds MD,
and
Papadimitriou JM.
Elucidation of aspects of murine skeletal muscle regeneration using local and whole body irradiation.
J Anat
181:
265-276,
1992.
77.
Robertson, TA,
Papadimitriou JM,
and
Grounds MD.
Fusion of myogenic cells to the newly sealed region of damaged myofibers in skeletal muscle regeneration.
Neuropathol Appl Neurobiol
19:
350-358,
1993[Web of Science][Medline].
78.
Robertson, TA,
Papadimitriou JM,
and
Grounds MD.
Fusion between a myogenic cell in the satellite cell position and undamaged adult myofiber segments.
Experientia
48:
394-395,
1992[Web of Science][Medline].
79.
Rommel, C,
Bodine SC,
Clarke BA,
Rossman R,
Nunez L,
Stitt TN,
Yancopoulos GD,
and
Glass DJ.
Mediation of IGF-1-induced skeletal myotube hypertrophy by PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK3 pathways.
Nat Cell Biol
3:
1009-1013,
2001[Web of Science][Medline].
80.
Rommel, C,
Clarke BA,
Zimmermann S,
Nuñez L,
Rossman R,
Reid K,
Moelling K,
Yancopoulos GD,
and
Glass DJ.
Differentiation stage-specific inhibition of the Raf-MEK-ERK pathway by Akt.
Science
286:
1738-1741,
1999
81.
Rosenblatt, JD,
and
Parry DJ.
Adaptation of rat extensor digitorum longus muscle to gamma irradiation and overload.
Pflügers Arch
423:
255-264,
1993[Web of Science][Medline].
82.
Rosenblatt, JD,
Yong D,
and
Parry DJ.
Satellite cell activity is required for hypertrophy of overloaded adult rat skeletal muscle.
Muscle Nerve
17:
608-613,
1994[Web of Science][Medline].
83.
Rosenthal, SM,
Brown EJ,
Brunetti A,
and
Goldfine ID.
Fibroblast growth factor inhibits insulin like growth factor-II (IGF-II) gene expression and increases IGF-I receptor abundance.
Mol Endocrinol
5:
678-684,
1991
84.
Rosenthal, SM,
and
Cheng ZQ.
Opposing early and late effects of insulin-like growth factor I on differentiation and the cell cycle regulatory retinoblastoma protein in skeletal myoblasts.
Proc Natl Acad Sci USA
92:
10307-10311,
1995
85.
Russell-Jones, DL,
and
Umpleby M.
Protein anabolic action of insulin, growth hormone and insulin-like growth factor-1.
Eur J Endocrinol
135:
631-642,
1996
86.
Sakuma, K,
Watanabe K,
Totsuka T,
Uramoto I,
Sano M,
and
Sakamoto K.
Differential adaptations of insulin-like growth factor-I, basic fibroblast growth factor, and leukemia inhibitory factor in the plantaris muscle of rats by mechanical overloading: an immunohistochemical study.
Acta Neuropathol (Berl)
95:
123-130,
1998[Medline].
87.
Salleo, A,
LaSpada G,
Falzea G,
Denaro MG,
and
Cicciarello R.
Response of satellite cells and muscle fibers to long-term compensatory hypertrophy.
J Submicrosc Cytol Pathol
15:
929-940,
1983.
88.
Samuel, DS,
Ewton DZ,
Coolican SA,
Petley TD,
McWade FJ,
and
Florini JR.
Raf-1 activation stimulates proliferation and inhibits IGF-stimulated differentiation in L6A1 myoblasts.
Horm Metab Res
31:
55-64,
1999[Web of Science][Medline].
89.
Sarbassov, DD,
and
Peterson CA.
Insulin receptor substrate-1 and phosphatidylinositol 3-kinase regulate extracellular signal-regulated kinase-dependent and -independent signaling pathways during myogenic differentiation.
Mol Endocrinol
12:
1870-1878,
1998
90.
Scheett, TP,
Mills PJ,
Ziegler MG,
Stoppani J,
and
Cooper DM.
Effect Of exercise on cytokines and growth mediators in prepubertal children.
Pediatr Res
46:
429-434,
1999[Web of Science][Medline].
91.
Schiaffino, S,
Pierobon Bormioli S,
and
Aloisi M.
The fate of newly formed satellite cells during compensatory muscle hypertrophy.
Virchows Arch
B21:
113-118,
1976.
92.
Schlechter, NL,
Russell SM,
Spencer EM,
and
Nicoll CS.
Evidence suggesting that the growth promoting effect of GH on cartilage in vivo is mediated by local production of somatomedia.
Proc Natl Acad Sci USA
83:
7923-7934,
1986
93.
Schultz, E.
Satellite cell behavior during skeletal muscle growth and regeneration.
Med Sci Sports Exerc
21:
S181-S186,
1989[Web of Science][Medline].
94.
Schultz, E,
and
McCormick KM.
Skeletal muscle satellite cells.
Rev Physiol Biochem Pharmacol
123:
213-257,
1994[Web of Science][Medline].
95.
Singleton, JR,
Baker BL,
and
Thorburn A.
Dexamethasone inhibits insulin-like growth factor signaling and potentiates myoblast apoptosis.
Endocrinology
141:
2945-2950,
2000
96.
Singleton, JR,
and
Feldman EL.
Insulin-like growth factor-I in muscle metabolism and myotherapies.
Neurobiol Dis
8:
541-554,
2001[Web of Science][Medline].
97.
Smith, LL.
Cytokine hypothesis of overtraining: a physiological adaptation to excessive stress?
Med Sci Sports Exerc
32:
317-331,
2000[Web of Science][Medline].
98.
Snow, MH.
Satellite cell response in rat soleus muscle undergoing hypertrophy due to surgical ablation of synergists.
Anat Rec
227:
437-446,
1990[Medline].
99.
Snow, MH.
Myogenic cell formation in regenerating rat skeletal muscle injured by mincing.
Anat Rec
188:
181-200,
1976.
100.
Sprenger, H,
Jacobs C,
Nain M,
Gressner AM,
Prinz H,
Wesemann W,
and
Gemsa D.
Enhanced release of cytokines, interleukin-2 receptors, and neopterin after long-distance running.
Clin Immunol Immunopathol
63:
188-195,
1992[Web of Science][Medline].
101.
Szalay, K,
Razga Z,
and
Duda E.
TNF inhibits myogenesis and downregulates the expression of myogenic regulatory factors myoD and myogenin.
Eur J Cell Biol
74:
391-398,
1997[Web of Science][Medline].
102.
Taipale, J,
and
Keski-Oja J.
Growth factors in the extracellular matrix.
FASEB J
11:
51-59,
1997[Abstract].
103.
Takahashi, T,
Fukuda K,
Pan J,
Kodama H,
Sano M,
Makino S,
Kato T,
Manabe T,
and
Ogawa S.
Characterization of insulin-like growth factor-I-induced activation of the JAK/STAT pathway in rat cardiomyocytes.
Circ Res
85:
884-891,
1999
104.
Talmadge, RJ,
Roy RR,
Chalmers GR,
and
Edgerton VR.
MHC and sarcoplasmic reticulum protein isoforms in functionally overloaded cat plantaris muscle fibers.
J Appl Physiol
80:
1296-1303,
1996
105.
Tamir, Y,
and
Bengal E.
Phosphoinositide 3-kinase induces the transcriptional activity of MEF2 proteins during muscle differentiation.
J Biol Chem
275:
34424-34432,
2000
106.
Thomas, G,
and
Hall MN.
TOR signaling and control of cell growth.
Curr Opin Cell Biol
9:
782-787,
1997[Web of Science][Medline].
107.
Tureckova, J,
Wilson EM,
Cappalonga JL,
and
Rotwein P.
Insulin-like growth factor-mediated muscle differentiation. Collaboration between phosphatidylinositol 3-kinase-akt-signaling pathways and myogenin.
J Biol Chem
276:
39264-39270,
2001
108.
Valentinis, B,
and
Baserga R.
IGF-I receptor signalling in transformation and differentiation.
Mol Pathol
54:
133-137,
2001
109.
Vandenburgh, HH,
Karlisch P,
Shansky J,
and
Feldstein R.
Insulin and IGF-I induce pronounced hypertrophy of skeletal myofibers in tissue culture.
Am J Physiol Cell Physiol
260:
C475-C484,
1991
110.
Vandromme, M,
Rochat A,
Meier R,
Carnac G,
Besser D,
Hemmings BA,
Fernandez A,
and
Lamb NJ.
Protein kinase B beta/Akt2 plays a specific role in muscle differentiation.
J Biol Chem
276:
8173-8179,
2001
111.
Vierck, J,
O'Reilly B,
Hossner K,
Antonio J,
Byrne K,
Bucci L,
and
Dodson M.
Satellite cell regulation following myotrauma caused by resistance exercise.
Cell Biol Int
24:
263-272,
2000[Web of Science][Medline].
112.
Wang, ZM,
Messi ML,
Renganathan M,
and
Delbono O.
Insulin-like growth factor-1 enhances rat skeletal muscle charge movement and L-type Ca2+ channel gene expression.
J Physiol
516:
331-341,
1999
113.
Weinstock, C,
Konig D,
Harnschmacher R,
Keul J,
Berg A,
and
Northoff H.
Effect of exhaustive exercise stress on the cytokine response.
Med Sci Sports Exerc
29:
345-354,
1997[Web of Science][Medline].
114.
Yan, Z,
Biggs RB,
and
Booth FW.
Insulin-like growth factor immunoreactivity increases in muscle after acute eccentric contractions.
J Appl Physiol
74:
410-414,
1993
115.
Yang, S,
Alnaqeeb M,
Simpson H,
and
Goldspink G.
Cloning and characterization of an IGF-1 isoform expressed in skeletal muscle subjected to stretch.
J Muscle Res Cell Motil
17:
487-495,
1996[Web of Science][Medline].
116.
Yarasheski, KE.
Growth hormone effects on metabolism, body composition, muscle mass, and strength.
Exerc Sport Sci Rev
22:
285-312,
1994[Medline].
117.
Yu, CF,
Roshan B,
Liu ZX,
and
Cantley LG.
ERK regulates the hepatocyte growth factor-mediated interaction of Gab1 and the phosphatidylinositol 3-kinase.
J Biol Chem
276:
32252-32258,
2001.
118.
Zammit, P,
and
Beauchamp J.
The skeletal muscle satellite cell: stem cell or son of stem cell?
Differentiation
68:
193-204,
2001[Web of Science][Medline].
119.
Zimmermann, S,
and
Moelling K.
Phosphorylation and regulation of Raf by Akt (protein kinase B).
Science
286:
1741-1744,
1999
120.
Zong, C,
Chan J,
Levy DE,
Horvath C,
Sadowski HB,
and
Wang L.
Mechanism of STAT3 activation by insulin-like growth factor I receptor.
J Biol Chem
275:
15099-15105,
2000
This article has been cited by other articles:
![]() |
B. D. Rodgers, J. P. Interlichia, D. K. Garikipati, R. Mamidi, M. Chandra, O. L. Nelson, C. E. Murry, and L. F. Santana Myostatin represses physiological hypertrophy of the heart and excitation\#8211;contraction coupling J. Physiol., October 15, 2009; 587(20): 4873 - 4886. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. K. O'Neil, L. R. Duffy, J. W. Frey, and T. A. Hornberger The role of phosphoinositide 3-kinase and phosphatidic acid in the regulation of mammalian target of rapamycin following eccentric contractions J. Physiol., July 15, 2009; 587(14): 3691 - 3701. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. PHILIPPOU, E. PAPAGEORGIOU, G. BOGDANIS, A. HALAPAS, A. SOURLA, M. MARIDAKI, N. PISSIMISSIS, and M. KOUTSILIERIS Expression of IGF-1 Isoforms after Exercise-induced Muscle Damage in Humans: Characterization of the MGF E Peptide Actions In Vitro In Vivo, July 1, 2009; 23(4): 567 - 575. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Miyazaki and K. A. Esser Cellular mechanisms regulating protein synthesis and skeletal muscle hypertrophy in animals J Appl Physiol, April 1, 2009; 106(4): 1367 - 1373. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y Liu, M Heinichen, K Wirth, D Schmidtbleicher, and J M Steinacker Response of growth and myogenic factors in human skeletal muscle to strength training Br. J. Sports Med., December 1, 2008; 42(12): 989 - 993. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. W. Hammers, E. K. Merritt, W. Matheny, M. L. Adamo, T. J. Walters, J. S. Estep, and R. P. Farrar Functional deficits and insulin-like growth factor-I gene expression following tourniquet-induced injury of skeletal muscle in young and old rats J Appl Physiol, October 1, 2008; 105(4): 1274 - 1281. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. K. Petrella, J.-s. Kim, D. L. Mayhew, J. M. Cross, and M. M. Bamman Potent myofiber hypertrophy during resistance training in humans is associated with satellite cell-mediated myonuclear addition: a cluster analysis J Appl Physiol, June 1, 2008; 104(6): 1736 - 1742. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. E. Spangenburg, D. Le Roith, C. W. Ward, and S. C. Bodine A functional insulin-like growth factor receptor is not necessary for load-induced skeletal muscle hypertrophy J. Physiol., January 1, 2008; 586(1): 283 - 291. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. M. Bamman, J. K. Petrella, J.-s. Kim, D. L. Mayhew, and J. M. Cross Cluster analysis tests the importance of myogenic gene expression during myofiber hypertrophy in humans J Appl Physiol, June 1, 2007; 102(6): 2232 - 2239. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Devaney, E. P. Hoffman, H. Gordish-Dressman, A. Kearns, E. Zambraski, and P. M. Clarkson IGF-II gene region polymorphisms related to exertional muscle damage J Appl Physiol, May 1, 2007; 102(5): 1815 - 1823. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. L. Olesen, K. M. Heinemeier, C. Gemmer, M. Kjaer, A. Flyvbjerg, and H. Langberg Exercise-dependent IGF-I, IGFBPs, and type I collagen changes in human peritendinous connective tissue determined by microdialysis J Appl Physiol, January 1, 2007; 102(1): 214 - 220. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Nemet, A. Eliakim, F. Zaldivar, and D. M. Cooper Effect of rhIL-6 infusion on GH->IGF-I axis mediators in humans Am J Physiol Regulatory Integrative Comp Physiol, December 1, 2006; 291(6): R1663 - R1668. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Abe, T. Matsunaga, K. Kameda, H. Tomita, T. Fujiwara, H. Ishizaka, H. Hanada, K. Fukui, I. Fukuda, T. Osanai, et al. Increased Level of Pericardial Insulin-Like Growth Factor-1 in Patients With Left Ventricular Dysfunction and Advanced Heart Failure J. Am. Coll. Cardiol., October 3, 2006; 48(7): 1387 - 1395. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Costelli, M. Muscaritoli, M. Bossola, F. Penna, P. Reffo, A. Bonetto, S. Busquets, G. Bonelli, F. J. Lopez-Soriano, G. B. Doglietto, et al. IGF-1 is downregulated in experimental cancer cachexia Am J Physiol Regulatory Integrative Comp Physiol, September 1, 2006; 291(3): R674 - R683. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. L. Olesen, K. M. Heinemeier, F. Haddad, H. Langberg, A. Flyvbjerg, M. Kjaer, and K. M. Baldwin Expression of insulin-like growth factor I, insulin-like growth factor binding proteins, and collagen mRNA in mechanically loaded plantaris tendon J Appl Physiol, July 1, 2006; 101(1): 183 - 188. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Oufattole, S. W.-J. Lin, B. Liu, D. Mascarenhas, P. Cohen, and B. D. Rodgers Ribonucleic Acid Polymerase II Binding Subunit 3 (Rpb3), a Potential Nuclear Target of Insulin-Like Growth Factor Binding Protein-3 Endocrinology, May 1, 2006; 147(5): 2138 - 2146. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. Toth, P. A. Ades, M. M. LeWinter, R. P. Tracy, and A. Tchernof Skeletal muscle myofibrillar mRNA expression in heart failure: relationship to local and circulating hormones J Appl Physiol, January 1, 2006; 100(1): 35 - 41. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-s. Kim, D. J. Kosek, J. K. Petrella, J. M. Cross, and M. M. Bamman Resting and load-induced levels of myogenic gene transcripts differ between older adults with demonstrable sarcopenia and young men and women J Appl Physiol, December 1, 2005; 99(6): 2149 - 2158. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. F Miller, J. L Olesen, M. Hansen, S. Dossing, R. M Crameri, R. J Welling, H. Langberg, A. Flyvbjerg, M. Kjaer, J. A Babraj, et al. Coordinated collagen and muscle protein synthesis in human patella tendon and quadriceps muscle after exercise J. Physiol., September 15, 2005; 567(3): 1021 - 1033. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. M. Bamman, R. C. Ragan, J.-s. Kim, J. M. Cross, V. J. Hill, S. C. Tuggle, and R. M. Allman Myogenic protein expression before and after resistance loading in 26- and 64-yr-old men and women J Appl Physiol, October 1, 2004; 97(4): 1329 - 1337. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Shavlakadze, M. Davies, J. D. White, and M. D. Grounds Early Regeneration of Whole Skeletal Muscle Grafts Is Unaffected by Overexpression of IGF-1 in MLC/mIGF-1 Transgenic Mice J. Histochem. Cytochem., July 1, 2004; 52(7): 873 - 883. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Haddad and G. R. Adams Inhibition of MAP/ERK kinase prevents IGF-I-induced hypertrophy in rat muscles J Appl Physiol, January 1, 2004; 96(1): 203 - 210. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Nemet, P. H. Connolly, A. M. Pontello-Pescatello, C. Rose-Gottron, J. K. Larson, P. Galassetti, and D. M. Cooper Negative energy balance plays a major role in the IGF-I response to exercise training J Appl Physiol, January 1, 2004; 96(1): 276 - 282. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. A. Frost and C. H. Lang Alteration of somatotropic function by proinflammatory cytokines J Anim Sci, January 1, 2004; 82(13_suppl): E100 - 109. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. E. McCall, D. L. Allen, F. Haddad, and K. M. Baldwin Transcriptional regulation of IGF-I expression in skeletal muscle Am J Physiol Cell Physiol, October 1, 2003; 285(4): C831 - C839. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |